var data={"title":"Perflutren lipid microspheres: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Perflutren lipid microspheres: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6755?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=perflutren-lipid-microspheres-patient-drug-information\" class=\"drug drug_patient\">see &quot;Perflutren lipid microspheres: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709204\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiopulmonary reactions: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes perflutren administration. Always have resuscitation equipment and trained personnel readily available.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208499\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Definity</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208500\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Definity</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208509\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208501\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cardiovascular imaging:</b> Dose should be given following baseline noncontrast echocardiography. Imaging should begin immediately following dose and compared to noncontrast image. Mechanical index for the ultrasound device should be set at &le;0.8.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV bolus: 10 microliters (mcL)/kg of activated product, followed by 10 mL saline flush; may repeat in 30 minutes (followed by 10 mL saline flush) if needed (maximum dose per imaging study: 2 bolus doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion: Initial: 4 mL/minute (or 240 mL/hour) of prepared infusion; titrate to achieve optimal image (maximum dose per imaging study: 1 IV infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Focal liver lesion evaluation (off-label use): </b>IV bolus: 0.1 to 0.6 mL per injection followed by a 5 mL saline flush; may be repeated at a minimum of every 5 minutes (ie, when most microbubbles have vanished) up to a maximum total dose of 10 microliters (mcL)/kg (Brannigan 2004; Jang 2009; WFUMB-EFSUMB [Claudon 2013]; Wilson 2007; Won 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062254\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370163\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370164\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208484\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]: OFP 6.52 mg/mL and lipid blend 0.75 mg/mL (2 mL) [following activation, forms a suspension containing perflutren lipid microspheres 1.2 x 10<sup>10</sup>/mL and OFP 1.1 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208474\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208486\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV bolus (undiluted):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiovascular imaging:</i> Administer only after activation in the Vialmix apparatus. Administer within 30 to 60 seconds of activation; follow each injection with a 10 mL saline flush.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Focal liver lesion evaluation (off-label use): </i>Administer only after activation in the Vialmix apparatus. Follow each injection with a 5 mL saline flush (Brannigan 2004; Jang 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV bolus (diluted): Administer only after activation in the Vialmix apparatus. Administer slowly up to 3 mL of solution; subsequent boluses of 1 to 2 mL may be used as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion rate: Initially, 4 mL/minute (or 240 mL/hour) up to 10 mL/minute (or 600 mL/hour); adjust flow rate for optimal image enhancement.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208485\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cardiovascular imaging:</b> Opacification of the left ventricular chamber and improvement of delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50548349\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Focal liver lesion evaluation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27979373\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Perflutren lipid microspheres may be confused with influenza virus vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208479\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, agitation, albuminuria, anaphylactoid reaction, anaphylactic shock, angioedema, arthralgia, atrial fibrillation, auditory impairment, bradycardia, bronchospasm, chest pain, coma, conjunctivitis, cough, diarrhea, dizziness, diaphoresis, dysgeusia, dyspnea, dyspepsia, ECG abnormality, edema (localized edema, mouth edema, palatal edema, peripheral edema, pharyngeal edema), eosinophilia, erythema, fatigue, fever, granulocytosis, hematoma, hot flash, hypertension, hypersensitivity reaction, hypertonia, hypotension, hypoxemia, hypoxia, injection site reaction, leg cramps, leukocytosis, leukopenia, loss of consciousness, pain, palpitations, paresthesia, pharyngitis, pruritus, respiratory distress, rhinitis, rigors, seizure, shock, skin rash (including erythematous rash), stridor, supraventricular tachycardia, swelling (facial swelling, swelling of eye, swelling of lips, swollen tongue, upper airway swelling), syncope, tachycardia, transient ischemic attacks, tremor, urticaria, ventricular fibrillation, ventricular tachycardia, vertigo, visual disturbance, vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208489\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to perflutren or to any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208477\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Postmarketing reports of anaphylactoid reactions (eg, shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, palatal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Monitor for signs and symptoms of anaphylactoid reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious cardiopulmonary reactions: <b>[US Boxed Warning]: Serious cardiopulmonary reactions (including fatalities) have occurred during or following administration; most serious reactions occur within 30 minutes of administration. </b><b>Assess all patients for the presence of any condition that precludes administration. <b> Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.</b></b> Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary artery syndromes, worsening or unstable HF, serious ventricular arrhythmias). However, multiple retrospective and prospective studies involving the use of perflutren-based ultrasound contrast agents have suggested they may be safely used in patients with significant cardiopulmonary disease (ie, acute coronary syndromes, heart failure, COPD, pulmonary hypertension) or critical illness (Dolan 2009; Kurt 2009; Kusnetzky 2008; Main 2008; Main 2014; Nucifora 2008; Wei 2008; Wei 2012; Weiss 2012; Wever-Pinzon 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. Safety of activated perflutren lipid microspheres with mechanical indices &gt;0.8 or use of end-systolic triggering has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac shunts: Assess patients with cardiac shunts for embolic phenomena following administration; perflutren lipid microspheres can bypass filtering by the lung and enter the arterial circulation. Patients with small degrees of right-to-left shunting through patent foramen ovales (those that result in transient appearance of saline contrast in the left atrium or ventricle and do not fill the left atrial or LV cavity) are not considered at an increased risk for microvascular occlusion with perflutren-based ultrasound contrast agents (ASE [Porter 2014]); Kalra 2014; Muskula 2017; Parker 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Product must be activated prior to use. For IV administration only; do not administer by intra-arterial injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299852\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222234\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10142&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208482\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208491\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617601\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if perflutren lipid microspheres is excreted in breast milk. The manufacturer recommends that caution be exercised when administering perflutren lipid microspheres to nursing women. Because of the rapid clearance of this drug, nursing mothers should pump and discard breast milk once after treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6188463\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiopulmonary reactions (rare); signs and symptoms of anaphylactoid reactions (rare). Monitor patient as appropriate based upon patient clinical disposition; specific monitoring parameters based upon perflutren lipid microspheres administration are not necessary (Muskula 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208476\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Activated perflutren lipid microspheres provide contrast enhancement of the endocardial borders during echocardiography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208488\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Immediate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IV bolus: 3.4 minutes; IV infusion: 7.1 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Octafluoropropane gas (OFP): Not metabolized; Phospholipid component: Metabolized to free fatty acids </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: OFP: 1.3 minutes (healthy patients); 1.9 minutes (patients with COPD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323664\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Definity Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.52 mg/mL (2 mL): $275.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208492\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Definity (AU, IL, KR, NZ);</li>\n      <li>Luminity (AT, CZ, DE, DK, ES, FI, HR, IE, LT, NL, PL, PT, RO, SE, SK);</li>\n      <li>Lumminity (MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15256618\"></a>Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. <i>Radiographics.</i> 2004;24(4):921-935. doi: 10.1148/rg.244035158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/15256618/pubmed\" target=\"_blank\" id=\"15256618\">15256618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23137926\"></a>Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. <i>Ultrasound Med Biol.</i> 2013;39(2):187-210. doi: 10.1016/j.ultrasmedbio.2012.09.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/23137926/pubmed\" target=\"_blank\" id=\"23137926\">23137926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Definity (perflutren lipid microspheres) [prescribing information]. North Billerica, MA: Lantheus Medical Imaging; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19118722\"></a>Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. <i>J Am Coll Cardiol.</i> 2009;53(1):32-38. doi: 10.1016/j.jacc.2008.08.066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19118722/pubmed\" target=\"_blank\" id=\"19118722\">19118722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18460662\"></a>Herzog CA, &ldquo;Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography,&rdquo; <i>JAMA </i>, 2008, 299(17):2023-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18460662/pubmed\" target=\"_blank\" id=\"18460662\">18460662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18834687\"></a>Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. <i>Eur J Radiol.</i> 2009;72(3):418-424. doi: 10.1016/j.ejrad.2008.08.011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18834687/pubmed\" target=\"_blank\" id=\"18834687\">18834687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalra A, Shroff GR, Erlien D, et al. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts. <i>JACC Cardiovasc Imaging.</i> 2014;7(2):206-207. doi: 10.1016/j.jcmg.2013.11.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24524748/pubmed\" target=\"_blank\" id=\"24524748\">24524748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. <i>J Am Coll Cardiol.</i> 2009;53(9):802-810. doi: 10.1016/j.jacc.2009.01.005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19245974/pubmed\" target=\"_blank\" id=\"19245974\">19245974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. <i>J Am Coll Cardiol.</i> 2008;51(17):1704-1706. doi: 10.1016/j.jacc.2008.03.006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18436124/pubmed\" target=\"_blank\" id=\"18436124\">18436124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). <i>Am J Cardiol.</i> 2008;102(12):1742-1746. doi: 10.1016/j.amjcard.2008.08.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19064035/pubmed\" target=\"_blank\" id=\"19064035\">19064035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Main ML, Hibberd MG, Ryan A, et al. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. <i>JACC Cardiovasc Imaging.</i> 2014;7(1):40-48. doi: 10.1016/j.jcmg.2013.08.012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24290568/pubmed\" target=\"_blank\" id=\"24290568\">24290568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muskula PR, Main ML. Safety with echocardiographic contrast agents. <i>Circ Cardiovascular Imaging.</i> 2017;10(4). pii: e005459. doi: 10.1161/CIRCIMAGING.116.005459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/28377467/pubmed\" target=\"_blank\" id=\"28377467\">28377467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucifora G, Marsan NA, Siebelink HM, et al. Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction. <i>Eur J Echocardiogr.</i> 2008;9(6):816-818. doi: 10.1093/ejechocard/jen167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18635517/pubmed\" target=\"_blank\" id=\"18635517\">18635517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.<i> Am J Cardiol.</i> 2013;112(7):1039-1045. doi: 10.1016/j.amjcard.2013.05.042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/23816393/pubmed\" target=\"_blank\" id=\"23816393\">23816393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography.<i> J Am Soc Echocardiogr.</i> 2014;27(8):797-810. doi: 10.1016/j.echo.2014.05.011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/25085408/pubmed\" target=\"_blank\" id=\"25085408\">25085408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. <i>J Am Soc Echocardiogr.</i> 2008;21(11):1202-1206. doi: 10.1016/j.echo.2008.07.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18848430/pubmed\" target=\"_blank\" id=\"18848430\">18848430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei K, Main ML, Lang RM, et al. The effect of Definity on systemic and pulmonary hemodynamics in patients. <i>J Am Soc Echocardiogr.</i> 2012;25(5):584-588. doi: 10.1016/j.echo.2012.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22365709/pubmed\" target=\"_blank\" id=\"22365709\">22365709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss RJ, Ahmad M, Villanueva F, et al. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. <i>J Am Soc Echocardiogr.</i> 2012;25(7):790-795. doi: 10.1016/j.echo.2012.04.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22560734/pubmed\" target=\"_blank\" id=\"22560734\">22560734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wever-Pinzon O, Suma V, Ahuja A, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study. <i>Eur Heart J Cardiovasc Imaging.</i> 2012;13(10):857-862. doi: 10.1093/ehjci/jes057.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22427401/pubmed\" target=\"_blank\" id=\"22427401\">22427401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17526609\"></a>Wilson SR, Jang HJ, Kim TK, et al. Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. <i>J Ultrasound Med.</i> 2007;26(6):775-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/17526609/pubmed\" target=\"_blank\" id=\"17526609\">17526609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24529054\"></a>Won SY, Singh N, Lim BG, et al. Hepatic contrast-enhanced ultrasound: impact of its introduction in the Australian context.<i> J Med Imaging Radiat Oncol.</i> 2014;58(1):38-45. doi: 10.1111/1754-9485.12093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24529054/pubmed\" target=\"_blank\" id=\"24529054\">24529054</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10142 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709204\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F208499\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F208500\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F208509\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F208501\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062254\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370163\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370164\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F208484\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F208474\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F208486\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F208485\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50548349\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27979373\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F208479\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F208489\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F208477\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299852\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222234\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F208482\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F208491\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617601\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6188463\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F208476\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F208488\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323664\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F208492\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10142|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=perflutren-lipid-microspheres-patient-drug-information\" class=\"drug drug_patient\">Perflutren lipid microspheres: Patient drug information</a></li></ul></div></div>","javascript":null}